Charles Ward 8-10-20 VIDEO… “Charlie Talks to Joseph Goode Twitter & Qanon Warrior! + 100k subs alert!!!!

I see this as a video with very significant information, particularly the KEY POINT listed below.

  • 2:00: KEY POINT: September 17, lockdown coming (blamed on “Second pandemic wave”; that is a smoke screen) for arresting the corrupt people running our countries. Lasts as long as it takes to arrest all the cabal they need to.
  • 20:20: Charles’ intel… HC and Clinton Foundation stole $6 billion from people of Haiti.
  • 23:40: Trump and Alliance are getting help from “Higher Beings”.
  • 27:40: Trump has taken control of CNN.

.

https://youtu.be/3zne-ZyILOk

Charles Ward 8-10-20 VIDEO… “Charlie Talks to Joseph Goode Twitter & Qanon Warrior! + 100k subs alert!!!!

I see this as a video with very significant information, particularly the KEY POINT listed below.

  • 2:00: KEY POINT: September 17, lockdown coming (blamed on “Second pandemic wave”; that is a smoke screen) for arresting the corrupt people running our countries. Lasts as long as it takes to arrest all the cabal they need to.
  • 20:20: Charles’ intel… HC and Clinton Foundation stole $6 billion from people of Haiti.
  • 23:40: Trump and Alliance are getting help from “Higher Beings”.
  • 27:40: Trump has taken control of CNN.

.

https://youtu.be/3zne-ZyILOk

Vit D, Magnesium and B12 Significantly Improve COVID Outcomes

You know I have been passionate about how useful optimal levels of vitamin D can be in lowering your COVID-19 risk. For the last few months I have been working on a campaign that I really need your help on. The new site is StopCOVIDCold and you can reach it by clicking the button below.

New Campaign to Spread the Word About Vitamin D

stopcovidcold

>>>>> Click Here <<<<<

Once you are on the site, there is a quiz you can take that will help you determine your risk for getting COVID-19 by answering a few questions that will only take you a few minutes. There is also an opportunity to upload a Facebook frame to your Facebook profile picture to help spread the word.

The media has failed miserably in educating the public on how to improve their immune system and has instead relied on the false hope of drugs, vaccines, social distancing and masks, all of which do nothing to improve your immune system.

We need your help in sharing this information with the elderly, and Blacks, who are most at risk of vitamin D deficiency.

The goal is to get this information out to tens, if not hundreds of millions of people. I simply can’t do it without your help. We plan on launching this information to 50-100 sites and I am giving readers of this site the first opportunity to participate in this process. I would deeply appreciate it if you could provide your feedback in the comment section below.

Vitamin D Deficiency Linked to More Severe COVID-19

Vitamin D, in particular, has emerged as an essential nutrient in the fight against COVID-19. In a letter to the editor published by Clinical Endocrinology, Dr. Grigorios Panagiotou, a clinical fellow in endocrinology and diabetes at the U.K.’s Newcastle upon Tyne Hospitals, found that COVID-19 patients admitted to intensive treatment units (ITUs) were more likely to be vitamin D deficient than those who were managed in medical wards.

Specifically, “only 19% of the ITU COVID-19 patients had 25(OH)D (vitamin D) levels greater than 50 nmol/L (20 ng/mL) versus 39.1% of non-ITU patients.”1

“Vitamin D receptors are highly expressed in B- and T-lymphocytes, suggesting a role in modulating innate and adaptive immune responses,” Panagiotou said in a news release. “[Vitamin D] levels reach their nadir at the end of winter, and low levels are associated with increased risk of acute respiratory tract infections during winter [and are] mitigated by vitamin D supplementation.”2

While this study did not find an association between vitamin D and COVID-19 fatality, it could be due to the small sample size and quick diagnosis and treatment of vitamin D deficiency.3 In fact, other research has linked vitamin D to increased death rates.

Researchers in Indonesia, who looked at data from 780 COVID-19 patients, found those with a vitamin D level between 21 ng/mL (52.5 nmol/L) and 29 ng/mL (72.5 nmol/L) had a 12.55 times higher risk of death than those with a level above 30 ng/mL.4 Having a level below 20 ng/mL was associated with a 19.12 times higher risk of death.

Even the French National Academy of Medicine released a press release in May 2020 detailing the importance of vitamin D for COVID-19.5 For COVID-19 patients over 60, they recommend vitamin D testing and if deficiency is found, a bolus dose of 50,000 to 100,000 IU. For anyone under the age of 60 who receives a positive COVID-19 test, they advise taking 800 IUs to 1,000 IUs of vitamin D per day.

A vitamin D review paper published in the journal Nutrients in April 2020 recommends higher amounts, stating:6

“To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d.

The goal should be to raise 25(OH)D concentrations above 40–60 ng/mL (100–150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.”

The best way to know how much vitamin D you need is to have your levels tested. Data from GrassrootsHealth’s D*Action studies suggest the optimal level for health and disease prevention is between 60 ng/mL and 80 ng/mL, while the cutoff for sufficiency appears to be around 40 ng/mL. In Europe, the measurements you’re looking for are 150 to 200 nmol/L and 100 nmol/L respectively.

I recently published a comprehensive vitamin D report in which I detail vitamin D’s mechanisms of action and how to ensure optimal levels. I recommend downloading and sharing that report with everyone you know, as the time to optimize your vitamin D level is now — before the fall and winter.

Additional Nutrient Strategies to Combat COVID-19

As with many viral infections, COVID-19 appears to have a nutritional component, by which you may lower your risk of severe outcomes by using vitamins and minerals therapeutically. Considering that current COVID-19 treatments are few and far between, and even “standard” therapies like mechanical ventilation appear to be backfiring,7 the use of natural solutions has caught the eye of numerous researchers.

Among them are researchers with the Singapore General Hospital and Duke-NUS Medical School, who set out to determine if a combination of vitamin D, magnesium and vitamin B12 would improve outcomes among COVID-19 patients aged 50 and older. Their basis was to attack the inflammatory component of the infection, noting:8

“A broad theme of immune hyper-inflammation has emerged as a key determinant of patient outcome with uncontrolled immune response postulated as a pathophysiologic factor in disease severity. Intuitively, immunomodulation becomes an attractive potential treatment strategy.”

Vitamin D, Magnesium, B12 Combo Improves COVID Outcomes

The cohort study involved 43 COVID-19 patents who were admitted to the Singapore General Hospital between January 15, 2020, and April 15, 2020. Seventeen of the patients received oral vitamin D3 (1,000 IU), magnesium (150 milligrams (mg)) and vitamin B12 (500 mcg) — together known as DMB — upon admission for a median of five days while 26 patients who did not receive DMB served as the control group.9

Significant benefits were seen among the DMB group, with only 17.6% requiring initiation of oxygen therapy during their hospitalization, compared to 61.5% of those in the control group. The requirement for oxygen is associated with an increased risk of needing intensive care, and the DMB group also benefited in this area.

Among those in the DMB group who required supplemental oxygen (three out of the 17 patients), two required ICU admission while one did not. Among the control group, all of those who needed supplemental oxygen required further ICU support. Nine of the DMB patients were given the combination within the first week of the onset of symptoms, and only one among them required oxygen therapy.

Overall, only three of the DMB patients deteriorated, two of whom deteriorated within 24 hours and may not have had enough time for the combo to work. The third case was started on DMB after seven days from onset of symptoms, and the researchers believe starting earlier in the course of the infection may be important.10

Further, DMB was protective even after accounting for other risk factors, including age and high blood pressure:11

“On univariate analysis, increasing age and hypertension demonstrated significantly higher odds ratio for oxygen therapy, while exposure to DMB therapy was associated with a significantly improved odds ratio. Multivariate analysis showed that DMB remained a significant protective factor against clinical deterioration after adjusting for age or hypertension separately.”

Combo Targets the Inflammatory Response

The researchers noted that many current therapeutics are focused on viral elimination instead of modulating the hyper-inflammation often seen in the disease. In fact, uncontrolled immune response has been suggested as a factor in disease severing, making immunomodulation “an attractive potential treatment strategy.”12 

For example, cytokines are a group of proteins that your body uses to control inflammation. If you have an infection, your body will release cytokines to help combat inflammation, but sometimes it releases more than it should.

If the cytokine release spirals out of control, the resulting “cytokine storm” becomes dangerous and is closely tied to sepsis, which may be an important contributor to the death of COVID-19 patients.13

“COVID-19 is therefore a multi-organ phenomenon and it is becoming evident that appropriate systemic inflammatory control is necessary for overall survival benefit,” the researchers explained, writing how vitamin D, magnesium and vitamin B12 present a unique three-pronged approach for tackling COVID-19:14 

“Vitamin D, through its effect on NFkB and other pathways, can attenuate various proinflammatory cytokine mediating the uncontrolled cytokine storm seen in severe COVID-19 with deficiency associated with severe COVID-19.

Magnesium is critical in the synthesis and activation of vitamin D, acting as a cofactor in many of the enzymes involved in vitamin D metabolism. Vitamin B12 is essential in supporting a healthy gut microbiome which has an important role in the development and function of both innate and adaptive immune systems.

This could be pivotal in preventing excessive immune reaction especially in COVID-19 patients with microbiota dysbiosis which were associated with severe disease.”

No side effects or adverse events occurred after DMB administration, which also provides an inexpensive, readily available solution that could be easily administered in doctor’s offices at the first onset of symptoms or even taken prophylactically among high-risk populations during outbreaks. There may even be benefit against other viral infections:15

“As all agents in this combination are readily available, safe and inexpensive, DMB can benefit a large swath of the world population especially in economically-challenged countries with limited or late access to vaccines and other therapies. DMB may also exhibit a generic efficacy against other viral infections with similar pathological mechanism.”

Magnesium Works in Concert With Vitamin D

Magnesium, which is required for the conversion of vitamin D into its active form, is important to ensure you’re properly utilizing the vitamin D you’re taking.

Research by GrassrootsHealth, based on data from nearly 3,000 individuals, reveals you need 244% more oral vitamin D if you’re not also taking magnesium and vitamin K2, which also works synergistically with vitamin D and helps prevent complications associated with excessive calcification in your arteries.16

What this means in practical terms is that if you take all three supplements in combination, you need far less oral vitamin D in order to achieve a healthy vitamin D level. This is also part of the success of the featured study’s DMB combination, which combines vitamin D with magnesium.

Importantly, a study published in October 2019 in the online issue of Diabetes Research and Clinical Practice also linked to low magnesium levels with both diabetes and high blood pressure, both of which are risk factors for severe COVID-19 outcomes.17

Dark green leafy vegetables are a good source of magnesium, and juicing your greens is an excellent way to boost your intake, although supplementation may also be necessary for some people.

If your magnesium intake from food is lacking, it would certainly be wise to supplement, either orally or topically. For oral supplementation, my personal preference is magnesium threonate, as it appears to be the most efficient at penetrating cell membranes, including your mitochondria and blood-brain barrier.

As a general rule, I recommend starting out on a dose of 200 mg of oral magnesium citrate per day, gradually increasing your dose until you develop slightly loose stools. To use this method, you need to use magnesium citrate, as it’s known for having a laxative effect. Once you know your cutoff, you can switch to other forms if you like. These include:

  • Magnesium glycinate, a powder with low solubility. Glycine is an important amino acid and precursor for glutathione.
  • Ionic magnesium found in molecular hydrogen tablets. Each water-soluble tablet has about 80 mg of highly bioavailable unbound magnesium ions, which is about 20% of the recommended daily allowance.
  • Magnesium threonate is another excellent choice as it seems it can efficiently penetrate the blood-brain barrier.
  • Magnesium malate, which dissolves very well in water. Malate is an intermediary in the Krebs cycle, so it likely contributes to ATP production.
  • Magnesium bisglycinate, which has high bioavailability.

As for vitamin B12, the third component of DMB, increasing B12-rich foods, such as grass fed beef liver, wild rainbow trout and wild sockeye salmon, in your diet can help, but for more serious deficiency you may need weekly shots of vitamin B12 or daily high-dose B12 supplements.

It’s encouraging, however, that simple and readily available nutrients such as these are showing such significant promise against COVID-19, and highlights the importance of optimizing your nutrient intake year-round to stay healthy and help ward off infectious disease.

Vit D, Magnesium and B12 Significantly Improve COVID Outcomes

You know I have been passionate about how useful optimal levels of vitamin D can be in lowering your COVID-19 risk. For the last few months I have been working on a campaign that I really need your help on. The new site is StopCOVIDCold and you can reach it by clicking the button below.

New Campaign to Spread the Word About Vitamin D

stopcovidcold

>>>>> Click Here <<<<<

Once you are on the site, there is a quiz you can take that will help you determine your risk for getting COVID-19 by answering a few questions that will only take you a few minutes. There is also an opportunity to upload a Facebook frame to your Facebook profile picture to help spread the word.

The media has failed miserably in educating the public on how to improve their immune system and has instead relied on the false hope of drugs, vaccines, social distancing and masks, all of which do nothing to improve your immune system.

We need your help in sharing this information with the elderly, and Blacks, who are most at risk of vitamin D deficiency.

The goal is to get this information out to tens, if not hundreds of millions of people. I simply can’t do it without your help. We plan on launching this information to 50-100 sites and I am giving readers of this site the first opportunity to participate in this process. I would deeply appreciate it if you could provide your feedback in the comment section below.

Vitamin D Deficiency Linked to More Severe COVID-19

Vitamin D, in particular, has emerged as an essential nutrient in the fight against COVID-19. In a letter to the editor published by Clinical Endocrinology, Dr. Grigorios Panagiotou, a clinical fellow in endocrinology and diabetes at the U.K.’s Newcastle upon Tyne Hospitals, found that COVID-19 patients admitted to intensive treatment units (ITUs) were more likely to be vitamin D deficient than those who were managed in medical wards.

Specifically, “only 19% of the ITU COVID-19 patients had 25(OH)D (vitamin D) levels greater than 50 nmol/L (20 ng/mL) versus 39.1% of non-ITU patients.”1

“Vitamin D receptors are highly expressed in B- and T-lymphocytes, suggesting a role in modulating innate and adaptive immune responses,” Panagiotou said in a news release. “[Vitamin D] levels reach their nadir at the end of winter, and low levels are associated with increased risk of acute respiratory tract infections during winter [and are] mitigated by vitamin D supplementation.”2

While this study did not find an association between vitamin D and COVID-19 fatality, it could be due to the small sample size and quick diagnosis and treatment of vitamin D deficiency.3 In fact, other research has linked vitamin D to increased death rates.

Researchers in Indonesia, who looked at data from 780 COVID-19 patients, found those with a vitamin D level between 21 ng/mL (52.5 nmol/L) and 29 ng/mL (72.5 nmol/L) had a 12.55 times higher risk of death than those with a level above 30 ng/mL.4 Having a level below 20 ng/mL was associated with a 19.12 times higher risk of death.

Even the French National Academy of Medicine released a press release in May 2020 detailing the importance of vitamin D for COVID-19.5 For COVID-19 patients over 60, they recommend vitamin D testing and if deficiency is found, a bolus dose of 50,000 to 100,000 IU. For anyone under the age of 60 who receives a positive COVID-19 test, they advise taking 800 IUs to 1,000 IUs of vitamin D per day.

A vitamin D review paper published in the journal Nutrients in April 2020 recommends higher amounts, stating:6

“To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d.

The goal should be to raise 25(OH)D concentrations above 40–60 ng/mL (100–150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.”

The best way to know how much vitamin D you need is to have your levels tested. Data from GrassrootsHealth’s D*Action studies suggest the optimal level for health and disease prevention is between 60 ng/mL and 80 ng/mL, while the cutoff for sufficiency appears to be around 40 ng/mL. In Europe, the measurements you’re looking for are 150 to 200 nmol/L and 100 nmol/L respectively.

I recently published a comprehensive vitamin D report in which I detail vitamin D’s mechanisms of action and how to ensure optimal levels. I recommend downloading and sharing that report with everyone you know, as the time to optimize your vitamin D level is now — before the fall and winter.

Additional Nutrient Strategies to Combat COVID-19

As with many viral infections, COVID-19 appears to have a nutritional component, by which you may lower your risk of severe outcomes by using vitamins and minerals therapeutically. Considering that current COVID-19 treatments are few and far between, and even “standard” therapies like mechanical ventilation appear to be backfiring,7 the use of natural solutions has caught the eye of numerous researchers.

Among them are researchers with the Singapore General Hospital and Duke-NUS Medical School, who set out to determine if a combination of vitamin D, magnesium and vitamin B12 would improve outcomes among COVID-19 patients aged 50 and older. Their basis was to attack the inflammatory component of the infection, noting:8

“A broad theme of immune hyper-inflammation has emerged as a key determinant of patient outcome with uncontrolled immune response postulated as a pathophysiologic factor in disease severity. Intuitively, immunomodulation becomes an attractive potential treatment strategy.”

Vitamin D, Magnesium, B12 Combo Improves COVID Outcomes

The cohort study involved 43 COVID-19 patents who were admitted to the Singapore General Hospital between January 15, 2020, and April 15, 2020. Seventeen of the patients received oral vitamin D3 (1,000 IU), magnesium (150 milligrams (mg)) and vitamin B12 (500 mcg) — together known as DMB — upon admission for a median of five days while 26 patients who did not receive DMB served as the control group.9

Significant benefits were seen among the DMB group, with only 17.6% requiring initiation of oxygen therapy during their hospitalization, compared to 61.5% of those in the control group. The requirement for oxygen is associated with an increased risk of needing intensive care, and the DMB group also benefited in this area.

Among those in the DMB group who required supplemental oxygen (three out of the 17 patients), two required ICU admission while one did not. Among the control group, all of those who needed supplemental oxygen required further ICU support. Nine of the DMB patients were given the combination within the first week of the onset of symptoms, and only one among them required oxygen therapy.

Overall, only three of the DMB patients deteriorated, two of whom deteriorated within 24 hours and may not have had enough time for the combo to work. The third case was started on DMB after seven days from onset of symptoms, and the researchers believe starting earlier in the course of the infection may be important.10

Further, DMB was protective even after accounting for other risk factors, including age and high blood pressure:11

“On univariate analysis, increasing age and hypertension demonstrated significantly higher odds ratio for oxygen therapy, while exposure to DMB therapy was associated with a significantly improved odds ratio. Multivariate analysis showed that DMB remained a significant protective factor against clinical deterioration after adjusting for age or hypertension separately.”

Combo Targets the Inflammatory Response

The researchers noted that many current therapeutics are focused on viral elimination instead of modulating the hyper-inflammation often seen in the disease. In fact, uncontrolled immune response has been suggested as a factor in disease severing, making immunomodulation “an attractive potential treatment strategy.”12 

For example, cytokines are a group of proteins that your body uses to control inflammation. If you have an infection, your body will release cytokines to help combat inflammation, but sometimes it releases more than it should.

If the cytokine release spirals out of control, the resulting “cytokine storm” becomes dangerous and is closely tied to sepsis, which may be an important contributor to the death of COVID-19 patients.13

“COVID-19 is therefore a multi-organ phenomenon and it is becoming evident that appropriate systemic inflammatory control is necessary for overall survival benefit,” the researchers explained, writing how vitamin D, magnesium and vitamin B12 present a unique three-pronged approach for tackling COVID-19:14 

“Vitamin D, through its effect on NFkB and other pathways, can attenuate various proinflammatory cytokine mediating the uncontrolled cytokine storm seen in severe COVID-19 with deficiency associated with severe COVID-19.

Magnesium is critical in the synthesis and activation of vitamin D, acting as a cofactor in many of the enzymes involved in vitamin D metabolism. Vitamin B12 is essential in supporting a healthy gut microbiome which has an important role in the development and function of both innate and adaptive immune systems.

This could be pivotal in preventing excessive immune reaction especially in COVID-19 patients with microbiota dysbiosis which were associated with severe disease.”

No side effects or adverse events occurred after DMB administration, which also provides an inexpensive, readily available solution that could be easily administered in doctor’s offices at the first onset of symptoms or even taken prophylactically among high-risk populations during outbreaks. There may even be benefit against other viral infections:15

“As all agents in this combination are readily available, safe and inexpensive, DMB can benefit a large swath of the world population especially in economically-challenged countries with limited or late access to vaccines and other therapies. DMB may also exhibit a generic efficacy against other viral infections with similar pathological mechanism.”

Magnesium Works in Concert With Vitamin D

Magnesium, which is required for the conversion of vitamin D into its active form, is important to ensure you’re properly utilizing the vitamin D you’re taking.

Research by GrassrootsHealth, based on data from nearly 3,000 individuals, reveals you need 244% more oral vitamin D if you’re not also taking magnesium and vitamin K2, which also works synergistically with vitamin D and helps prevent complications associated with excessive calcification in your arteries.16

What this means in practical terms is that if you take all three supplements in combination, you need far less oral vitamin D in order to achieve a healthy vitamin D level. This is also part of the success of the featured study’s DMB combination, which combines vitamin D with magnesium.

Importantly, a study published in October 2019 in the online issue of Diabetes Research and Clinical Practice also linked to low magnesium levels with both diabetes and high blood pressure, both of which are risk factors for severe COVID-19 outcomes.17

Dark green leafy vegetables are a good source of magnesium, and juicing your greens is an excellent way to boost your intake, although supplementation may also be necessary for some people.

If your magnesium intake from food is lacking, it would certainly be wise to supplement, either orally or topically. For oral supplementation, my personal preference is magnesium threonate, as it appears to be the most efficient at penetrating cell membranes, including your mitochondria and blood-brain barrier.

As a general rule, I recommend starting out on a dose of 200 mg of oral magnesium citrate per day, gradually increasing your dose until you develop slightly loose stools. To use this method, you need to use magnesium citrate, as it’s known for having a laxative effect. Once you know your cutoff, you can switch to other forms if you like. These include:

  • Magnesium glycinate, a powder with low solubility. Glycine is an important amino acid and precursor for glutathione.
  • Ionic magnesium found in molecular hydrogen tablets. Each water-soluble tablet has about 80 mg of highly bioavailable unbound magnesium ions, which is about 20% of the recommended daily allowance.
  • Magnesium threonate is another excellent choice as it seems it can efficiently penetrate the blood-brain barrier.
  • Magnesium malate, which dissolves very well in water. Malate is an intermediary in the Krebs cycle, so it likely contributes to ATP production.
  • Magnesium bisglycinate, which has high bioavailability.

As for vitamin B12, the third component of DMB, increasing B12-rich foods, such as grass fed beef liver, wild rainbow trout and wild sockeye salmon, in your diet can help, but for more serious deficiency you may need weekly shots of vitamin B12 or daily high-dose B12 supplements.

It’s encouraging, however, that simple and readily available nutrients such as these are showing such significant promise against COVID-19, and highlights the importance of optimizing your nutrient intake year-round to stay healthy and help ward off infectious disease.

Flu Vaccination Associated With Increased Viral Shedding

When your body is infected with a disease-causing virus such as influenza, the virus is “shed” into the environment, via your saliva and other bodily fluids and skin lesions. If someone comes in contact with that shed virus, it’s possible that they, too, will become infected with the virus.

There’s still a lot of unknowns when it comes to viral shedding. How long a person sheds a virus, when shedding occurs and whether it occurs at the onset of symptoms or prior to symptoms, varies by virus and are influenced by a person’s age, health status and even weight.1

That viruses are shed from their hosts is common knowledge. However, the topic of viral shedding isn’t one you’ll hear about often when it comes to live attenuated viral vaccines, examples of which include measles, mumps, rubella (MMR), vaccinia (smallpox), varicella, zoster (which contains the same virus as varicella vaccine but in much higher amount), yellow fever, rotavirus and influenza (intranasal).2

Live viral vaccines use a weakened (or attenuated) version of the virus, which is typically passed through a living cell culture or other host, such as chicken embryo, many times over until it becomes weakened to a point that it’s not likely to make you sick when it’s injected, swallowed or inhaled.

That being said, it’s still a live vaccine-strain virus — one that can be shed like any virus — and research suggests that vaccination may increase viral shedding in the case of influenza.3

Flu Vaccine Recipients Shed 6.3 Times More Virus Into the Air

In a study published in PNAS, University of Maryland researchers revealed not only that influenza virus may be spread via simple breathing (i.e., no sneezing or coughing required) but also that repeated vaccination increases the amount of influenza virus released into the air.4

“Little is known about the amount and infectiousness of influenza virus shed into exhaled breath. This contributes to uncertainty about the importance of airborne influenza transmission,” the researchers noted. “We show that sneezing is rare and not important for — and that coughing is not required for — influenza virus aerosolization.”5

This is important, as it means that even someone who’s not actively sneezing or coughing can still potentially transmit the influenza virus to others.

Further, someone who’s recently received the live attenuated influenza vaccine (LAIV) may also potentially actively shed and transmit the virus. According to the study, in fact, people who were vaccinated for influenza shed more than six times more virus into the air than those who were not:6

“Self-reported vaccination for the current season was associated with a trend toward higher viral shedding in fine-aerosol samples; vaccination with both the current and previous year’s seasonal vaccines, however, was significantly associated with greater fine-aerosol shedding in unadjusted and adjusted models.

In adjusted models, we observed 6.3 times more aerosol shedding among cases with vaccination in the current and previous season compared with having no vaccination in those two seasons.”

Annual Vaccination May Actually Reduce Your Protection

Receiving a flu vaccination to prevent type A or B influenza is not nearly as cut-and-dry as health officials would have you believe. There are many unanswered questions that deserve further research, like the possibility that getting repeated annual flu shots may increase your susceptibility to influenza. In a 2013 study, it was found that those who received the influenza vaccine two years in a row got no significant protection during the current flu season.7,8

Another finding revealed by the study was that vaccination failed to prevent household transmission once influenza was introduced, with adults being particularly at risk despite vaccination.9 Again in 2019, researchers found that vaccine effectiveness was lower against certain types of flu (H3N2 and B) for those vaccinated during two consecutive flu seasons compared to those vaccinated in the current season only.10

The possibility that repeated vaccination may reduce effectiveness, and that annual vaccination may increase aerosol viral shedding, demands more investigation. According to the featured study researchers:11

“The association of current and prior year vaccination with increased shedding of influenza A might lead one to speculate that certain types of prior immunity promote lung inflammation, airway closure, and aerosol generation. This first observation of the phenomenon needs confirmation.

If confirmed, this observation, together with recent literature suggesting reduced protection with annual vaccination, would have implications for influenza vaccination recommendations and policies.”

It’s possible, for instance, that after vaccination, you may become a contagious silent carrier of disease. A person with influenza who fully expresses symptoms of fever, body aches, cough and other signs of respiratory illness would likely stay at home.

However, a vaccinated individual, who is silently contagious, would go to work and into stores and other public places and be unaware they are spreading infection, which can be done even via regular breathing.

This is an especially important fact for vaccinated health care workers, who move freely among patients in hospitals and other medical facilities because everyone assumes vaccinated medical personnel are “immune” to influenza if they get a flu shot every year, even though they could potentially be transmitting influenza to hospital patients, including those in the ICU.

CDC: Virus Shedding ‘Common’ After Receipt of LAIV

Although you may be surprised to learn that virus shedding occurs after certain vaccinations, even the U.S. Centers for Disease Control and Prevention (CDC), in their “Safety of Influenza Vaccines” report for professionals,12 states that shedding of the live attenuated vaccine virus is “common” after receipt of LAIV. They cite numerous studies confirming as such, including:

  • Among 345 LAIV3 recipients, 29% had detectable virus in their nasal secretions, with maximal shedding occurring within two days of vaccination13
  • In a study of 200 children aged 6 months through 59 months, 79% shed at least one vaccine virus; shedding was most common among younger children, with 89% of 6- to 23-month-olds shedding at least one vaccine virus14

The live influenza vaccine is FluMist, which is approved for nonpregnant women as well as anyone aged 2 to 49 years. It’s administered in the form of a nasal spray.

While the CDC states that the live type A and B vaccine strain influenza viruses in FluMist are too weak to actually give recipients influenza, according to the CDC, “transmission of shed LAIV vaccine viruses from vaccine recipients to unvaccinated persons has been documented …”15

MedImmune, the company that developed FluMist, is also aware that the vaccine sheds vaccine-strain virus. In its prescribing information, they describe a study on the transmission of vaccine-strain influenza viruses from vaccinated children to nonvaccinated children in a day care setting.

In 80% of the FluMist recipients, at least one vaccine-strain influenza virus was isolated anywhere from one to 21 days following vaccination. They further noted, “One placebo subject had mild symptomatic Type B virus infection confirmed as a transmitted vaccine virus by a FluMist recipient in the same playgroup.”16

How Often Does Vaccine Virus Transmission Occur?

According to the CDC, “The estimated probability of transmission of vaccine virus within a contact group with a single LAIV recipient in this population [a child care center] was 0.58%,” however in a child care setting it’s likely that multiple children would have received LAIV at any given time.17

However, there’s no way to know for sure how often vaccine-strain live virus shedding and disease transmission actually occurs, since it’s not being actively monitored or tested for.

Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center (NVIC), wrote a special report, “The Emerging Risks of Live Virus and Viral Vectored Vaccines: Vaccine Strain Virus Infection, Shedding and Transmission,” which contains over 200 references and delves into virus shedding and vaccine virus shedding. She noted:18

“There is no active surveillance and testing for evidence of vaccine strain live virus shedding, transmission and infection among populations routinely being given multiple doses of live virus vaccines, including measles vaccine. Therefore, it is unknown exactly how many vaccinated children and adults in the U.S. or other countries are shedding and transmitting vaccine strain live viruses.

Whether or not vaccine strain live virus shedding, transmission and infection is causing undiagnosed or misdiagnosed health problems, especially among people with severe immune deficiencies or autoimmune and other immune system disorders, is an open question.”

A Live Attenuated COVID-19 Vaccine Is Being Produced

The featured study has implications for COVID-19, which is still a mystery in terms of transmission and treatment. It’s unknown, for instance, if Sars-CoV-2, the virus that causes COVID-19, has airborne transmission potential in addition to being spread by more direct contact or droplets.

Airborne transmission appears likely,19 however, raising even more concerns considering the development of a live attenuated COVID-19 vaccine has begun.

In June 2020, biotechnology company Meissa Vaccines announced that it has initiated preclinical studies and manufacturing of a live attenuated COVID-19 vaccine,20 which was derived by modifying the company’s live attenuated RSV vaccine candidate.

Whether a live attenuated COVID-19 vaccine will end up causing recipients to shed vaccine-strain virus into the air remains to be seen, but there are inherent risks. Even Martin Moore, Ph.D., co-founder and CEO of Meissa Vaccines, told BioSpace about the potential for virus shedding. BioSpace reported:21

“Moore explained that if a virus is attenuated based on one or two gene mutations, the virus could revert to being infectious in the vaccine recipient and they can shed live virus, spreading it to others. This is the worst-case scenario and why there are such strict safety standards for vaccines, especially LAVs [live attenuated vaccines].

‘Safety is critical, there are no cutting corners with safety,’ explained Moore. ‘Coronaviruses, in particular, are prone to genetic recombination, so using a live attenuated coronavirus in a vaccine would run the risk of becoming infectious again.’”

In terms of both influenza and any novel COVID-19 vaccines licensed by the Food and Drug Administration (FDA) and recommended by the CDC, it’s important to be aware of the differences between attenuated live virus vaccines and inactivated vaccines, especially if you’re in a vulnerable population, such as very young children, the elderly, pregnant and breastfeeding women and people with acute or chronic health problems or a compromised immune system.

There remain many unanswered questions regarding live virus vaccines and their ultimate impact on public health.

Flu Vaccination Associated With Increased Viral Shedding

When your body is infected with a disease-causing virus such as influenza, the virus is “shed” into the environment, via your saliva and other bodily fluids and skin lesions. If someone comes in contact with that shed virus, it’s possible that they, too, will become infected with the virus.

There’s still a lot of unknowns when it comes to viral shedding. How long a person sheds a virus, when shedding occurs and whether it occurs at the onset of symptoms or prior to symptoms, varies by virus and are influenced by a person’s age, health status and even weight.1

That viruses are shed from their hosts is common knowledge. However, the topic of viral shedding isn’t one you’ll hear about often when it comes to live attenuated viral vaccines, examples of which include measles, mumps, rubella (MMR), vaccinia (smallpox), varicella, zoster (which contains the same virus as varicella vaccine but in much higher amount), yellow fever, rotavirus and influenza (intranasal).2

Live viral vaccines use a weakened (or attenuated) version of the virus, which is typically passed through a living cell culture or other host, such as chicken embryo, many times over until it becomes weakened to a point that it’s not likely to make you sick when it’s injected, swallowed or inhaled.

That being said, it’s still a live vaccine-strain virus — one that can be shed like any virus — and research suggests that vaccination may increase viral shedding in the case of influenza.3

Flu Vaccine Recipients Shed 6.3 Times More Virus Into the Air

In a study published in PNAS, University of Maryland researchers revealed not only that influenza virus may be spread via simple breathing (i.e., no sneezing or coughing required) but also that repeated vaccination increases the amount of influenza virus released into the air.4

“Little is known about the amount and infectiousness of influenza virus shed into exhaled breath. This contributes to uncertainty about the importance of airborne influenza transmission,” the researchers noted. “We show that sneezing is rare and not important for — and that coughing is not required for — influenza virus aerosolization.”5

This is important, as it means that even someone who’s not actively sneezing or coughing can still potentially transmit the influenza virus to others.

Further, someone who’s recently received the live attenuated influenza vaccine (LAIV) may also potentially actively shed and transmit the virus. According to the study, in fact, people who were vaccinated for influenza shed more than six times more virus into the air than those who were not:6

“Self-reported vaccination for the current season was associated with a trend toward higher viral shedding in fine-aerosol samples; vaccination with both the current and previous year’s seasonal vaccines, however, was significantly associated with greater fine-aerosol shedding in unadjusted and adjusted models.

In adjusted models, we observed 6.3 times more aerosol shedding among cases with vaccination in the current and previous season compared with having no vaccination in those two seasons.”

Annual Vaccination May Actually Reduce Your Protection

Receiving a flu vaccination to prevent type A or B influenza is not nearly as cut-and-dry as health officials would have you believe. There are many unanswered questions that deserve further research, like the possibility that getting repeated annual flu shots may increase your susceptibility to influenza. In a 2013 study, it was found that those who received the influenza vaccine two years in a row got no significant protection during the current flu season.7,8

Another finding revealed by the study was that vaccination failed to prevent household transmission once influenza was introduced, with adults being particularly at risk despite vaccination.9 Again in 2019, researchers found that vaccine effectiveness was lower against certain types of flu (H3N2 and B) for those vaccinated during two consecutive flu seasons compared to those vaccinated in the current season only.10

The possibility that repeated vaccination may reduce effectiveness, and that annual vaccination may increase aerosol viral shedding, demands more investigation. According to the featured study researchers:11

“The association of current and prior year vaccination with increased shedding of influenza A might lead one to speculate that certain types of prior immunity promote lung inflammation, airway closure, and aerosol generation. This first observation of the phenomenon needs confirmation.

If confirmed, this observation, together with recent literature suggesting reduced protection with annual vaccination, would have implications for influenza vaccination recommendations and policies.”

It’s possible, for instance, that after vaccination, you may become a contagious silent carrier of disease. A person with influenza who fully expresses symptoms of fever, body aches, cough and other signs of respiratory illness would likely stay at home.

However, a vaccinated individual, who is silently contagious, would go to work and into stores and other public places and be unaware they are spreading infection, which can be done even via regular breathing.

This is an especially important fact for vaccinated health care workers, who move freely among patients in hospitals and other medical facilities because everyone assumes vaccinated medical personnel are “immune” to influenza if they get a flu shot every year, even though they could potentially be transmitting influenza to hospital patients, including those in the ICU.

CDC: Virus Shedding ‘Common’ After Receipt of LAIV

Although you may be surprised to learn that virus shedding occurs after certain vaccinations, even the U.S. Centers for Disease Control and Prevention (CDC), in their “Safety of Influenza Vaccines” report for professionals,12 states that shedding of the live attenuated vaccine virus is “common” after receipt of LAIV. They cite numerous studies confirming as such, including:

  • Among 345 LAIV3 recipients, 29% had detectable virus in their nasal secretions, with maximal shedding occurring within two days of vaccination13
  • In a study of 200 children aged 6 months through 59 months, 79% shed at least one vaccine virus; shedding was most common among younger children, with 89% of 6- to 23-month-olds shedding at least one vaccine virus14

The live influenza vaccine is FluMist, which is approved for nonpregnant women as well as anyone aged 2 to 49 years. It’s administered in the form of a nasal spray.

While the CDC states that the live type A and B vaccine strain influenza viruses in FluMist are too weak to actually give recipients influenza, according to the CDC, “transmission of shed LAIV vaccine viruses from vaccine recipients to unvaccinated persons has been documented …”15

MedImmune, the company that developed FluMist, is also aware that the vaccine sheds vaccine-strain virus. In its prescribing information, they describe a study on the transmission of vaccine-strain influenza viruses from vaccinated children to nonvaccinated children in a day care setting.

In 80% of the FluMist recipients, at least one vaccine-strain influenza virus was isolated anywhere from one to 21 days following vaccination. They further noted, “One placebo subject had mild symptomatic Type B virus infection confirmed as a transmitted vaccine virus by a FluMist recipient in the same playgroup.”16

How Often Does Vaccine Virus Transmission Occur?

According to the CDC, “The estimated probability of transmission of vaccine virus within a contact group with a single LAIV recipient in this population [a child care center] was 0.58%,” however in a child care setting it’s likely that multiple children would have received LAIV at any given time.17

However, there’s no way to know for sure how often vaccine-strain live virus shedding and disease transmission actually occurs, since it’s not being actively monitored or tested for.

Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center (NVIC), wrote a special report, “The Emerging Risks of Live Virus and Viral Vectored Vaccines: Vaccine Strain Virus Infection, Shedding and Transmission,” which contains over 200 references and delves into virus shedding and vaccine virus shedding. She noted:18

“There is no active surveillance and testing for evidence of vaccine strain live virus shedding, transmission and infection among populations routinely being given multiple doses of live virus vaccines, including measles vaccine. Therefore, it is unknown exactly how many vaccinated children and adults in the U.S. or other countries are shedding and transmitting vaccine strain live viruses.

Whether or not vaccine strain live virus shedding, transmission and infection is causing undiagnosed or misdiagnosed health problems, especially among people with severe immune deficiencies or autoimmune and other immune system disorders, is an open question.”

A Live Attenuated COVID-19 Vaccine Is Being Produced

The featured study has implications for COVID-19, which is still a mystery in terms of transmission and treatment. It’s unknown, for instance, if Sars-CoV-2, the virus that causes COVID-19, has airborne transmission potential in addition to being spread by more direct contact or droplets.

Airborne transmission appears likely,19 however, raising even more concerns considering the development of a live attenuated COVID-19 vaccine has begun.

In June 2020, biotechnology company Meissa Vaccines announced that it has initiated preclinical studies and manufacturing of a live attenuated COVID-19 vaccine,20 which was derived by modifying the company’s live attenuated RSV vaccine candidate.

Whether a live attenuated COVID-19 vaccine will end up causing recipients to shed vaccine-strain virus into the air remains to be seen, but there are inherent risks. Even Martin Moore, Ph.D., co-founder and CEO of Meissa Vaccines, told BioSpace about the potential for virus shedding. BioSpace reported:21

“Moore explained that if a virus is attenuated based on one or two gene mutations, the virus could revert to being infectious in the vaccine recipient and they can shed live virus, spreading it to others. This is the worst-case scenario and why there are such strict safety standards for vaccines, especially LAVs [live attenuated vaccines].

‘Safety is critical, there are no cutting corners with safety,’ explained Moore. ‘Coronaviruses, in particular, are prone to genetic recombination, so using a live attenuated coronavirus in a vaccine would run the risk of becoming infectious again.’”

In terms of both influenza and any novel COVID-19 vaccines licensed by the Food and Drug Administration (FDA) and recommended by the CDC, it’s important to be aware of the differences between attenuated live virus vaccines and inactivated vaccines, especially if you’re in a vulnerable population, such as very young children, the elderly, pregnant and breastfeeding women and people with acute or chronic health problems or a compromised immune system.

There remain many unanswered questions regarding live virus vaccines and their ultimate impact on public health.